RELAY MEDICAL Toronto, Ontario--(Newsfile Corp. - September 4, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalm™ System Prototype Cartridge.
In conjunction with the previously announced ENGAGE grant with McMaster University's Manufacturing Research Institute (MMRI), the Company has completed the fabrication of the prototype HemoPalm™ cartridge, a key component of the HemoPalm™ analysis system. MMRI produced the prototype by micromachining and testing of cartridge operation including calibration fluid pouch activation and microfluidic flow has already begun. Development of CO-oximetry calibration algorithms at McMaster University is underway.
Below is a photo of the see-through HemoPalm™ prototype cartridge identifying key components. The see through material allows easy observation of fluid flow during cartridge testing.
To view an enhanced version of the see-through HemoPalm™ prototype cartridge, please visit:
https://orders.newsfilecorp.com/files/952/17126_chrome1enhanced.jpg
"This is the first major step in the completion of the HemoPalm™ system alpha prototype. The cartridge is a critical element of the system and contains several novel features that set it apart from competitive products. Micromachining of the prototype cartridges has allowed rapid design modifications when needed, avoiding the time and cost of modifications to conventional plastic injection moulds. We are very pleased with our collaboration with McMaster University." said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.
The Company is also pleased to present a 3D schematic video of the HemoPalm™ Analyzer system which demonstrates the sequence of operations commencing with the scanning of the cartridge for identification followed by spectroscopic CO-oximetry measurement, biosensor fluid calibration and biosensor measurement of blood gases and electrolytes.
If you cannot view the video above, please visit:
https://www.youtube.com/watch?v=PQ38FLtRTSk
ChroMedX recently announced the engagement of Polygenesis Corporation to complete the development of the biosensor technology aspect of the HemoPalm™ system as well as complete the development of the prototype analyzer.
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.
Follow ChroMedX Corp.:
Facebook: facebook.com/ChroMedXcorp
Twitter: www.twitter.com/ChroMedXcorp
Investor Relations:
Shawn Overton
d. 647-528-9344
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
soverton@ChroMedX.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are basedon the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.
